Calamos Advisors LLC lifted its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 65.7% during the fourth quarter, HoldingsChannel.com reports. The firm owned 481,632 shares of the biopharmaceutical company’s stock after acquiring an additional 190,921 shares during the quarter. Calamos Advisors LLC’s holdings in Alexion Pharmaceuticals were worth $57,598,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Valeo Financial Advisors LLC acquired a new stake in Alexion Pharmaceuticals in the 3rd quarter valued at approximately $147,000. Dupont Capital Management Corp acquired a new stake in Alexion Pharmaceuticals in the 3rd quarter valued at approximately $156,000. BT Investment Management Ltd acquired a new stake in Alexion Pharmaceuticals in the 3rd quarter valued at approximately $165,000. Beacon Investment Advisory Services Inc. acquired a new stake in Alexion Pharmaceuticals in the 3rd quarter valued at approximately $201,000. Finally, Invictus RG acquired a new stake in Alexion Pharmaceuticals in the 3rd quarter valued at approximately $202,000. 95.38% of the stock is currently owned by institutional investors.
A number of equities research analysts recently issued reports on the company. BMO Capital Markets lifted their target price on Alexion Pharmaceuticals from $177.00 to $180.00 and gave the company an “outperform” rating in a research report on Friday, February 9th. Deutsche Bank set a $161.00 price target on Alexion Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, February 9th. Morgan Stanley boosted their price target on Alexion Pharmaceuticals from $148.00 to $151.00 and gave the stock an “overweight” rating in a research report on Friday, February 9th. Citigroup lowered their price target on Alexion Pharmaceuticals from $173.00 to $170.00 and set a “buy” rating on the stock in a research report on Friday, February 9th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $151.00 price target on shares of Alexion Pharmaceuticals in a research report on Friday, February 9th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and twenty-one have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $152.77.
Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at $117.45 on Thursday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.62 and a current ratio of 3.10. Alexion Pharmaceuticals, Inc. has a one year low of $96.18 and a one year high of $149.34. The company has a market capitalization of $26,233.78, a P/E ratio of 23.34, a PEG ratio of 1.10 and a beta of 1.16.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The company had revenue of $909.70 million during the quarter, compared to the consensus estimate of $880.38 million. During the same period in the previous year, the company posted $1.26 EPS. The firm’s revenue for the quarter was up 9.5% compared to the same quarter last year. research analysts anticipate that Alexion Pharmaceuticals, Inc. will post 6.12 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Alexion Pharmaceuticals, Inc. (ALXN) Shares Bought by Calamos Advisors LLC” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3229858/alexion-pharmaceuticals-inc-alxn-shares-bought-by-calamos-advisors-llc.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.